CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 54 of the 58 references it cites were found in a registry or an index.
Abstract
Introduction CDKN2A (p16) inactivation is common in lung cancer and occurs via homozygous deletions, methylation of promoter region, or point mutations. Although p16 promoter methylation has been linked to KRAS mutation and smoking, the associations between p16 inactivation mechanisms and other common genetic mutations and smoking status are still controversial or unknown.Methods We determined all three p16 inactivation mechanisms with the use of multiple methodologies for genomic status, methylation, RNA, and protein expression, and correlated them with EGFR, KRAS, STK11 mutations and smoking status in 40 cell lines and 45 tumor samples of primary non-small-cell lung carcinoma. We also performed meta-analyses to investigate the impact of smoke exposure on p16 inactivation.Results p16 inactivation was the major mechanism of RB pathway perturbation in non-small-cell lung carcinoma, with homozygous deletion being the most frequent method, followed by methylation and the rarer point mutations. Inactivating mechanisms were tightly correlated with loss of mRNA and protein expression. p16 inactivation occurred at comparable frequencies regardless of mutational status of EGFR, KRAS, and STK11, however, the major inactivation mechanism of p16 varied. p16 methylation was linked to KRAS mutation but was mutually exclusive with EGFR mutation. Cell lines and tumor samples demonstrated similar results. Our meta-analyses confirmed a modest positive association between p16 promoter methylation and smoking.Conclusion Our results confirm that all the inactivation mechanisms are truly associated with loss of gene product and identify specific associations between p16 inactivation mechanisms and other genetic changes and smoking status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“KRAS mutations are also correlated with the epigenetic silencing of CDKN2A by promoter hypermethylation [124].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“The random-effects model was used for heterogeneous studies whereas the fixed-effects model was applied if the studies were homogeneous.(30) To prevent one of the studies from dominating the results by contributing a larger number of samples or a big effect size, we adopted the leave-one-out strategy by removing data…”
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2021) · doi:10.1002/9781119558378 · Cited by 9,799
Primary, Secondary, and Meta-Analysis of Research
GLASS, G. V. (1976) · Educational Researcher · doi:10.3102/0013189x005010003 · Cited by 4,890
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 2×
“None of the EGFR-mutated cases demonstrated p16 promoter methylation, which has been identified as a common mechanism of p16 inactivation in lung adenocarcinomas in this as well as in a number of other studies.(9,12,25) Our analysis revealed that EGFR mutations and p16 methylation were mutually exclusive in all cases,…”
SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD
Howlader, N. (2011) · Medical Entomology and Zoology · Cited by 2,612
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Self-citationMapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · cited 1×
“Several new potential targets for therapeutic approaches have also been identified recently.(15,16) A study of these mutations may eventually lead to novel therapeutic applications.”
Cited by
Implications of Genetic and Epigenetic Alterations of CDKN2A (p16 INK4a ) in Cancer
Zhao, R., Choi, B. Y., Lee, M.-H., Bode, A. M., & Dong, Z. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.017 · Cited by 425
“However, changes in STK11 (also known as LKB1), a gene frequentlymutated in lung adenocarcinomas, have no impact on CDKN2A inactivationmechanisms (Tam et al., 2013).”
BackgroundInfluentialLung cancer epigenetics: From knowledge to applications
Duruisseaux, M., & Esteller, M. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.005 · Cited by 283
Molecular and epigenetic mechanisms of Cr(VI)-induced carcinogenesis
Chen, Q. Y., Murphy, A., Sun, H., & Costa, M. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114636 · Cited by 174
Self-citationCells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival
Oser, M. G., Fonseca, R., Chakraborty, A. A., Brough, R., Spektor, A., Jennings, R. B., Flaifel, A., Novak, J. S., Gulati, A., Buss, E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0389 · Cited by 173
An Expression Signature as an Aid to the Histologic Classification of Non–Small Cell Lung Cancer
Girard, L., Rodriguez-Canales, J., Behrens, C., Thompson, D. M., Botros, I. W., Tang, H., Xie, Y., Rekhtman, N., Travis, W. D., Wistuba, I. I., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2900 · Cited by 154
“RNA was prepared with TRIzol (Invitrogen) as previously described from ADCs resected in British Columbia, Canada and collected by Dr. Stephen Lam (British Columbia Cancer Agency, Vancouver, BC, Canada) (16, 17).”
Self-citation
Metadata
- Authors
- Tam, K. W., Zhang, W., Soh, J., Stastny, V., Chen, M., Sun, H., Thu, K., Rios, J. J., Yang, C., Marconett, C. N., Selamat, S. A., Laird-Offringa, I. A., Taguchi, A., Hanash, S., Shames, D., Ma, X., Zhang, M. Q., Lam, W. L., & Gazdar, A.
- Affiliations
- BC Cancer Agency (CA)
- The University of Texas Southwestern Medical Center (US)
- The University of Texas at Dallas (US)
- Texas Scottish Rite Hospital for Children (US)
- University of Southern California (US)
- Fred Hutch Cancer Center (US)
- Genentech (US)
- Corresponding author
- Gazdar, Adi
- ORCID
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 8
- Issue
- 11
- Pages
- 1378-1388
- ISSN
- 1556-0864 (ISSN-L)
- PMC
- PMC3951422
- OpenAlex
- W1971623971
- Cited by
- 109
- References
- 58
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 11 · 2023: 13 · 2022: 5 · 2021: 18 · 2020: 8 · 2019: 6 · 2018: 6 · 2017: 8 · 2016: 9 · 2015: 1 · 2014: 5
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 761 d)
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Canary Foundation
- University of Texas Southwestern Medical Center (P50CA70907)
- National Institutes of Health
- National Human Genome Research Institute (R01HG001696, HG001696)
- National Cancer Institute ((P50-CA70907, P50CA070907, U01CA086402)
- National Institute of Environmental Health Sciences (U01ES017166)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- CDKN2A, p16, non-small cell lung cancer, p16 promoter methylation, homozygous deletion, smoking, KRAS mutation, EGFR mutation, STK11 mutation, Rb pathway, tumor suppressor inactivation, gene expression loss
- MeSH terms
- AMP-Activated Protein Kinase Kinases, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Prognosis, Proto-Oncogene Proteins, Smoking, Tumor Cells, Cultured, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, Carcinoma, Adenosquamous, Carcinoma, Large Cell, ras Proteins, DNA Methylation, Cyclin-Dependent Kinase Inhibitor p16, DNA Copy Number Variations, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1097/jto.0b013e3182a46c0c
- The paper
- Tam, K. W., Zhang, W., Soh, J., Stastny, V., Chen, M., Sun, H., Thu, K., Rios, J. J., Yang, C., Marconett, C. N., Selamat, S. A., Laird-Offringa, I. A., Taguchi, A., Hanash, S., Shames, D., Ma, X., Zhang, M. Q., Lam, W. L., & Gazdar, A. (2013). CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. https://doi.org/10.1097/jto.0b013e3182a46c0c
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.